After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...
A Reuters report regarding the rejection of Unilever's $68 billion offer for GlaxoSmithKline’s consumer healthcare assets is raising questions, including whether Unilever should raise the bid and risk ...
(Reuters) – Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline’s consumer healthcare assets was rejected — should it raise the bid and risk overpaying or seek ...
GSK has outperformed both the healthcare sector and S&P 500 this year, which is notable considering the spectre of high ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...
Recent performance and why GSK stock is back on radar GSK (LSE:GSK) has quietly delivered a strong run this year, with the share price up about 34% year to date and roughly 44% over the past year, ...
Clinical trials are an essential component of cancer drug development. GSK is transforming trial design to improve patient experience and research output qualityBy Zeshaan Rasheed, Senior Vice ...
Experts question Pfizer's failure to inform pregnant women of safety signal in GSK RSV vaccine trial
A debate has broken out over whether Pfizer should have told pregnant women taking part in its maternal respiratory syncytial virus (RSV) vaccine trial that a trial of a similar GSK vaccine was ...
March 31 (Reuters) - The success or failure of GlaxoSmithKline's experimental heart drug darapladib remains "an open question" and will hinge on a second pivotal clinical study, the company's chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback